Skip to content

Brain patterns of anticipatory and consummatory reward

Brain patterns of anticipatory and consummatory reward

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28090
Enrollment
26
Registered
2013-11-05
Start date
2013-12-12
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Light products, anticipatory and consummatory reward, taste activation (brain activation). Light producten, verwachting van een beloning, consumptie van een beloning, smaak activatie (brein activatie).

Interventions

Participants are exposured to three different labels, a light label a regular label and a 'neutral' label, and two tastants, a regular beverage and a neutral control stimulus. There are three task c

Sponsors

Wageningen University, Division of Human Nutrition P.O. Box 9101 6700 HB Wageningen The Netherlands +31 (0)317 489111 +31 (0)317 483999 info@wur.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18-35 years; 2. Being female; 3. BMI: 18.5 – 25.0 kg/m2; 4. Healthy (as judged by the participant); 5. Being right handed; 6. Willing to comply with the study procedures; 7. Willing to be informed about incidental findings of pathology; 8. Having given written informed consent; 9. Successful completion of the training session.

Exclusion criteria

Exclusion criteria: 1. Restraint eating (women: score > 2.80) 2. Lack of appetite 3. Having difficulties with swallowing/eating 4. Usage of an energy restricted diet during the last two months 5. Weight loss or weight gain of 5 kg or more during the last two months 6. Stomach or bowel diseases 7. Diabetes, thyroid disease, kidney disease and other endocrine disorders 8. Having a history of neurological disorders 9. Having taste or smell disorders 10. Having schizophrenia or another serious mental illnesses 11. Usage of daily medication other than oral contraceptives, Paracetamol or hay fever tablets 12. Pregnancy during the last 6 months, having the intention to become pregnant or lactating 13. Smoking on average more than one cigarette/cigar a day 14. Being allergic/intolerant for products under study 15. Exclusive consumption of ‘light’ versions of beverages 16. Avoidance of ‘light’ versions of beverages 17. Disliking the beverages under study 18. Working or doing an internship/thesis at the group Sensory science and eating behavior (WUR) 19. Current participation in other nutrition related or medical research 20. Having a history of or current alcohol consumption of on average more than 28 units per week 21. Having a contra-indication to MRI scanning (including, but not limited to): Claustrophobia Epilepsy Pacemakers and defibrillators Intraorbital or intraocular metallic fragments Ferromagnetic implants Presence of non-removable metal objects in the mouth

Design outcomes

Secondary

MeasureTime frame
The 1st secondary study parameter/endpoint is the correlation between brain activation in response to exposure to an anticipatory or a consummatory reward and reaction times and errors (push/pull measure). In addition, two groups will be made based on the product choice outcome and anticipatory reward responses and consummatory reward responses are compared between those groups (i.e. there is looked at the group*reward response interaction). The 2nd secondary study parameter/endpoint is the correlation between brain activation in response to exposure to an anticipatory or a consummatory reward and subject characteristics like reward sensitivity, delayed discounting, impulsivity, health attitude, stress, executive functioning and food neophobia.

Primary

MeasureTime frame
The main study parameters/endpoints are (1) the difference in brain activation between an anticipatory reward and a consummatory reward and (2) the difference in brain activation between a consummatory reward labeled as light versus labeled as regular.

Contacts

Public ContactInge Rijn, van

Bomenweg 2

inge.vanrijn@wur.nl+31 (0)317 480759

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)